{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim WS"],"funding":["NCI NIH HHS"],"pagination":["65-73"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11701429"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(1)"],"pubmed_abstract":["<h4>Purpose</h4>Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.<h4>Patients and methods</h4>Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy. Acimtamig (200 mg) was administered once weekly in 8-week cycles. The primary endpoint was the overall response rate by fluorodeoxyglucose-PET per independent review committee; secondary and exploratory endpoints included duration of response, safety, progression-free survival, and overall survival.<h4>Results</h4>The overall response rate in 108 patien"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas."],"pmcid":["PMC11701429"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Alexis K","Pinto S","Horwitz S","Overesch A","Mikhailova N","Radeski D","Domingo Domenech E","Hajela P","Ravenstijn P","Pietzko K","Shortt J","Garcia L","Elbadri R","Kim WS","Zinzani PL","Sawas A","Emig M","Ribrag V"],"additional_accession":[]},"is_claimable":false,"name":"A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.","description":"<h4>Purpose</h4>Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.<h4>Patients and methods</h4>Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy. Acimtamig (200 mg) was administered once weekly in 8-week cycles. The primary endpoint was the overall response rate by fluorodeoxyglucose-PET per independent review committee; secondary and exploratory endpoints included duration of response, safety, progression-free survival, and overall survival.<h4>Results</h4>The overall response rate in 108 patien","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-01T11:04:29.571Z","creation":"2026-04-08T11:32:32.89Z"},"accession":"S-EPMC11701429","cross_references":{"pubmed":["39531538"],"doi":["10.1158/1078-0432.CCR-24-1913"]}}